INT151095

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 2006
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 13
Total Number 14
Disease Relevance 4.40
Pain Relevance 1.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (ATP6V0A1) nucleolus (ATP6V0A1) plasma membrane (ATP6V0A1)
nucleus (ATP6V0A1) transmembrane transport (ATP6V0A1) cytoplasm (ATP6V0A1)
Anatomy Link Frequency
urinary bladder 1
vesicles 1
CHO 1
ATP6V0A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
adenocard 91 100.00 Very High Very High Very High
agonist 65 100.00 Very High Very High Very High
antagonist 64 100.00 Very High Very High Very High
cytokine 10 98.24 Very High Very High Very High
Inflammation 44 97.08 Very High Very High Very High
Dopamine 44 83.24 Quite High
nociceptor 1 74.00 Quite High
imagery 12 58.88 Quite High
Hippocampus 2 17.52 Low Low
addiction 16 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Infection 336 100.00 Very High Very High Very High
Death 24 100.00 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 320 99.92 Very High Very High Very High
Targeted Disruption 16 99.82 Very High Very High Very High
Mouth Disease 31 99.00 Very High Very High Very High
Apoptosis 11 98.60 Very High Very High Very High
INFLAMMATION 48 97.08 Very High Very High Very High
Disease 25 96.56 Very High Very High Very High
Benign Prostatic Hypertrophy 2 94.00 High High
Hypoxia 2 87.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These human genes include early endosome antigen 1 (EEA1; 72%), Rab6 interacting protein 2 (ELKS; 63%) and ATPase (ATP6V0A1; 77%).
Gene_expression (include) of ATP6V0A1
1) Confidence 0.48 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.21 Pain Relevance 0
To further validate the findings obtained from the initial screen, we have selected these genes (CLTC, AP2B1, DNM2, ARRB1, ATP6V0A1 & ARPC1B) for re-confirming their inhibitory effects on DENV infection.
Gene_expression (infection) of ATP6V0A1 associated with infection
2) Confidence 0.48 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.53 Pain Relevance 0
-Arrestin (ARRB1) is involved in the desensitization of receptors by targeting them to clathrin-coated vesicles through a RhoA and actin-dependent mechanism [60].
Gene_expression (vesicles) of clathrin-coated in vesicles
3) Confidence 0.48 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.09 Pain Relevance 0
Cystatin B and Annexin A1 were found by Bostanci et al.(29) only in healthy volunteers and not in developing inflammatory disease.
Neg (not) Gene_expression (found) of A1 associated with inflammation and disease
4) Confidence 0.22 Published 2010 Journal Journal of Proteome Research Section Body Doc Link PMC2950674 Disease Relevance 0.85 Pain Relevance 0.12
OBJECTIVES: To examine the expressions of transient receptor potential (TRP) channel A1 and TRPM8 in the human urogenital organs (urinary bladder and prostate) and how these expressions change in association with bladder outlet obstruction (BOO) or benign prostatic hyperplasia (BPH).
Spec (examine) Gene_expression (expressions) of A1 in urinary bladder associated with benign prostatic hypertrophy
5) Confidence 0.21 Published 2008 Journal Urology Section Abstract Doc Link 18384850 Disease Relevance 0.19 Pain Relevance 0.07
Binding to membranes expressing rat and human A1 and A3 adenosine receptors was not significant, and binding in membranes of HEK 293 cells expressing human A2A receptors was of low affinity (KD > 50 nM).
Gene_expression (expressing) of A1 associated with adenocard
6) Confidence 0.18 Published 2006 Journal Purinergic Signal Section Body Doc Link PMC2096665 Disease Relevance 0 Pain Relevance 0.32
The knock-down of ATP6V0A1 and CLTC (at concentration of 50 nM) produced the strongest inhibition of DENV infection. siRNA smart pool-based deconvolution assays targeting CLTC, AP2B1, DNM2, ARRB1, ATP6V0A1 and ARPC1B were also performed to ensure that inhibitory effects on DENV infection observed in the primary screen was specific and not due to off-target gene effects of the siRNA primary screen. 30 nM of each specific individual siRNA of the smart pool (4 specific siRNAs) directed against each of the respective genes were reverse transfected into RD cells and subsequently subjected to DENV infection.
Gene_expression (produced) of ATP6V0A1 associated with targeted disruption and infection
7) Confidence 0.17 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.74 Pain Relevance 0
Whilst for A1, A2A and A3 adenosine subtypes good agonists and antagonists have been synthesized allowing a plethora of binding and functional studies, no high-affinity analogues have been identified for the A2B receptors until a couple of years ago, and neither high-affinity nor selective antagonists had been introduced until 2001 [3, 7, 8].
Neg (no) Gene_expression (synthesized) of A1 associated with adenocard, antagonist and agonist
8) Confidence 0.14 Published 2006 Journal Purinergic Signal Section Body Doc Link PMC2096665 Disease Relevance 0.42 Pain Relevance 0.58
For their pharmacological evaluation, cyclic adenosine monophosphate (cAMP) determinations were carried out in Chinese hamster ovary (CHO) cells expressing human A1 receptors (CHO:hA1) vs. radioligand dissociation experiments on rat-brain membranes.
Gene_expression (expressing) of A1 in CHO associated with adenocard
9) Confidence 0.11 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721769 Disease Relevance 0 Pain Relevance 0.08
p2 = .046), reflecting greater delay discounting measured impulsivity in A1+ individuals, and an interaction effect between the two genotypes (F (1, 164) = 7.63, p = .006, ?
Gene_expression (individuals) of A1 associated with attention deficit hyperactivity disorder
10) Confidence 0.07 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1781951 Disease Relevance 0.43 Pain Relevance 0
The principal analyses used 2 (A1+/A1-) × 2 (L+/L-) factorial analyses of variance (ANOVAs), using a two-tailed significance criterion of p < .05 and partial eta squared (?
Gene_expression (/) of A1
11) Confidence 0.07 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1781951 Disease Relevance 0.07 Pain Relevance 0
The principal analyses used 2 (A1+/A1-) × 2 (L+/L-) factorial analyses of variance (ANOVAs), using a two-tailed significance criterion of p < .05 and partial eta squared (?
Gene_expression (/) of A1
12) Confidence 0.07 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1781951 Disease Relevance 0.07 Pain Relevance 0
Thus, particularly steep delay discounting (increased impulsivity) in those with both long DRD4 and A1 DRD2 alleles may reflect the concurrent variation in two key points in the reward decision-making loops spanning the corticostriatal-mesolimbic axis.
Gene_expression (alleles) of A1 associated with attention deficit hyperactivity disorder
13) Confidence 0.07 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1781951 Disease Relevance 0.18 Pain Relevance 0.07
The genes TPT1 (or histamine releasing factor), cytokine induced apoptosis inhibitor 1 (cIAP-1), mitochondrial PUMA (BBC3), cathepsin B (CTSB), ATP6V0A1, cathepsin L and LAMP2, all of which are associated with cell-death related responses, were differentially expressed after the 1 h exposure to L. plantarum WCFS1.
Gene_expression (expressed) of ATP6V0A1 associated with apoptosis, death and cytokine
14) Confidence 0.04 Published 2008 Journal BMC Genomics Section Body Doc Link PMC2519092 Disease Relevance 0.60 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox